Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Clinical trial NCT04203160 · TERMINATED
Trial details
- NCT number
- NCT04203160
- Sponsor
- University of Michigan Rogel Cancer Center
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-23
- Primary completion
- 2024-04-16
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.